

# Stacey C Sigmon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11240379/publications.pdf>

Version: 2024-02-01

89  
papers

2,892  
citations

159358

30  
h-index

182168

51  
g-index

90  
all docs

90  
docs citations

90  
times ranked

2571  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of the Covid-19 Pandemic on Smoking Among Vulnerable Populations. <i>Nicotine and Tobacco Research</i> , 2023, 25, 282-290.	1.4	7
2	Effects of Reduced Nicotine Content Cigarettes on Fractional Exhaled Nitric Oxide and Self-Reported Respiratory Health Outcomes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage. <i>Nicotine and Tobacco Research</i> , 2022, 24, 135-140.	1.4	5
3	National Trends in Suicide Thoughts and Behavior among US Adults with Opioid Use Disorder from 2015 to 2020. <i>Substance Use and Misuse</i> , 2022, 57, 876-885.	0.7	4
4	Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder. <i>Pain Medicine</i> , 2021, 22, 1205-1212.	0.9	2
5	Within-subject evaluation of interim buprenorphine treatment during waitlist delays. <i>Drug and Alcohol Dependence</i> , 2021, 220, 108532.	1.6	5
6	Cumulative vulnerabilities as a potential moderator of response to reduced nicotine content cigarettes. <i>Preventive Medicine</i> , 2021, 152, 106714.	1.6	5
7	Efficacy and Cost-Benefit of Onsite Contraceptive Services With and Without Incentives Among Women With Opioid Use Disorder at High Risk for Unintended Pregnancy. <i>JAMA Psychiatry</i> , 2021, 78, 1071-1078.	6.0	11
8	Opioid use disorder treatment in rural settings: The primary care perspective. <i>Preventive Medicine</i> , 2021, 152, 106765.	1.6	10
9	Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont. <i>Preventive Medicine</i> , 2021, 152, 106817.	1.6	4
10	Sucrose subjective response and eating behaviors among individuals with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 227, 109017.	1.6	5
11	Potential Moderating Effects of Sex/Gender on the Acute Relative Reinforcing and Subjective Effects of Reduced Nicotine Content Cigarettes in Vulnerable Populations. <i>Nicotine and Tobacco Research</i> , 2020, 22, 878-884.	1.4	3
12	Relating individual differences in nicotine dependence severity to underpinning motivational and pharmacological processes among smokers from vulnerable populations. <i>Preventive Medicine</i> , 2020, 140, 106189.	1.6	6
13	Changes in Cigarette Consumption With Reduced Nicotine Content Cigarettes Among Smokers With Psychiatric Conditions or Socioeconomic Disadvantage. <i>JAMA Network Open</i> , 2020, 3, e2019311.	2.8	42
14	Perceptions of long-acting reversible contraception among women receiving medication for opioid use disorder in Vermont. <i>Contraception</i> , 2020, 101, 333-337.	0.8	10
15	Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107879.	1.6	5
16	Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid use disorder and other vulnerabilities.. <i>Experimental and Clinical Psychopharmacology</i> , 2020, 28, 714-723.	1.3	6
17	Examining effects of unit price on preference for reduced nicotine content cigarettes and smoking rate. <i>Preventive Medicine</i> , 2019, 128, 105823.	1.6	3
18	Higher smoking prevalence among United States adults with co-occurring affective and drug use diagnoses. <i>Addictive Behaviors</i> , 2019, 99, 106112.	1.7	21

#	ARTICLE	IF	CITATIONS
19	Innovations in efforts to expand treatment for opioid use disorder. Preventive Medicine, 2019, 128, 105818.	1.6	9
20	Reasons for non-medical use of prescription opioids among young adults: Role of educational status. Preventive Medicine, 2019, 128, 105684.	1.6	3
21	Evaluating the utility of the modified cigarette evaluation questionnaire and cigarette purchase task for predicting acute relative reinforcing efficacy of cigarettes varying in nicotine content. Drug and Alcohol Dependence, 2019, 197, 56-64.	1.6	10
22	Potential Moderating Effects of Psychiatric Diagnosis and Symptom Severity on Subjective and Behavioral Responses to Reduced Nicotine Content Cigarettes. Nicotine and Tobacco Research, 2019, 21, S29-S37.	1.4	8
23	Examining Age as a Potential Moderator of Response to Reduced Nicotine Content Cigarettes in Vulnerable Populations. Nicotine and Tobacco Research, 2019, 21, S49-S55.	1.4	8
24	Fentanyl exposure among patients seeking opioid treatment. Journal of Substance Abuse Treatment, 2019, 96, 23-25.	1.5	19
25	Response to Reduced Nicotine Content in Vulnerable Populations: Effect of Menthol Status. Tobacco Regulatory Science (discontinued), 2019, 5, 135-142.	0.2	10
26	Response to reduced nicotine content cigarettes among smokers differing in tobacco dependence severity. Preventive Medicine, 2018, 117, 15-23.	1.6	27
27	Associations between opioid and nicotine dependence in nationally representative samples of United States adult daily smokers. Drug and Alcohol Dependence, 2018, 186, 167-170.	1.6	45
28	Response to reduced nicotine content cigarettes among smokers with chronic health conditions. Preventive Medicine Reports, 2018, 12, 321-329.	0.8	4
29	Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder. JAMA Internal Medicine, 2018, 178, 764.	2.6	148
30	Co-occurring vulnerabilities and menthol use in U.S. young adult cigarette smokers: Findings from Wave 1 of the PATH Study, 2013-2014. Preventive Medicine, 2018, 117, 43-51.	1.6	11
31	A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study. Drug and Alcohol Dependence, 2018, 190, 224-228.	1.6	15
32	Promoting smoking abstinence among patients with chronic obstructive pulmonary disease: Initial feasibility. Preventive Medicine Reports, 2018, 11, 176-179.	0.8	5
33	Feasibility of an interactive voice response system for daily monitoring of illicit opioid use during buprenorphine treatment.. Psychology of Addictive Behaviors, 2018, 32, 956-960.	1.4	4
34	Tobacco withdrawal among opioid-dependent smokers.. Experimental and Clinical Psychopharmacology, 2018, 26, 119-124.	1.3	7
35	Interim buprenorphine treatment during delays to comprehensive treatment: Changes in psychiatric symptoms.. Experimental and Clinical Psychopharmacology, 2018, 26, 403-409.	1.3	20
36	Reduced Nicotine Content Cigarettes and Cannabis Use in Vulnerable Populations. Tobacco Regulatory Science (discontinued), 2018, 4, 84-91.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Vermont Hub-and-Spoke Model of Care for Opioid Use Disorder: Development, Implementation, and Impact. <i>Journal of Addiction Medicine</i> , 2017, 11, 286-292.	1.4	162
38	Development of a Self-Report Measure of Reward Sensitivity:A Test in Current and Former Smokers. <i>Nicotine and Tobacco Research</i> , 2017, 19, 723-728.	1.4	7
39	Addiction Potential of Cigarettes With Reduced Nicotine Content in Populations With Psychiatric Disorders and Other Vulnerabilities to Tobacco Addiction. <i>JAMA Psychiatry</i> , 2017, 74, 1056.	6.0	101
40	Does Tobacco Abstinence Decrease Reward Sensitivity? A Human Laboratory Test. <i>Nicotine and Tobacco Research</i> , 2017, 19, 677-685.	1.4	60
41	Response to varying the nicotine content of cigarettes in vulnerable populations: an initial experimental examination of acute effects. <i>Psychopharmacology</i> , 2017, 234, 89-98.	1.5	32
42	Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. <i>Journal of Substance Abuse Treatment</i> , 2017, 72, 117-125.	1.5	33
43	Food and Drug Administration approval of sustained-release buprenorphine for treatment of opioid dependence: realizing its potential. <i>Addiction</i> , 2017, 112, 386-387.	1.7	20
44	Preliminary validity of the modified Cigarette Evaluation Questionnaire in predicting the reinforcing effects of cigarettes that vary in nicotine content.. <i>Experimental and Clinical Psychopharmacology</i> , 2017, 25, 473-478.	1.3	16
45	Financial incentives to promote extended smoking abstinence in opioid-maintained patients: a randomized trial. <i>Addiction</i> , 2016, 111, 903-912.	1.7	26
46	Interim Buprenorphine vs. Waiting List for Opioid Dependence. <i>New England Journal of Medicine</i> , 2016, 375, 2504-2505.	13.9	67
47	Behavioral risk assessment for infectious diseases (BRAID): Self-report instrument to assess injection and noninjection risk behaviors in substance users. <i>Drug and Alcohol Dependence</i> , 2016, 168, 69-75.	1.6	10
48	Opioid Overdose Experience, Risk Behaviors, and Knowledge in Drug Users from a Rural Versus an Urban Setting. <i>Journal of Substance Abuse Treatment</i> , 2016, 71, 1-7.	1.5	47
49	Using behavioral economic theory to increase use of effective contraceptives among opioid-maintained women at risk of unintended pregnancy. <i>Preventive Medicine</i> , 2016, 92, 62-67.	1.6	38
50	Additive burdens of malnutrition, poverty, and substance abuse. <i>Lancet, The</i> , 2016, 388, 1879-1880.	6.3	6
51	Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers. <i>Addictive Behaviors</i> , 2015, 42, 189-193.	1.7	9
52	Bridging waitlist delays with interim buprenorphine treatment: Initial feasibility. <i>Addictive Behaviors</i> , 2015, 51, 136-142.	1.7	31
53	Characterizing opioid withdrawal during double-blind buprenorphine detoxification. <i>Drug and Alcohol Dependence</i> , 2015, 151, 47-55.	1.6	26
54	The Untapped Potential of Office-Based Buprenorphine Treatment. <i>JAMA Psychiatry</i> , 2015, 72, 395.	6.0	65

#	ARTICLE	IF	CITATIONS
55	Increases in Body Mass Index Following Initiation of Methadone Treatment. <i>Journal of Substance Abuse Treatment</i> , 2015, 51, 59-63.	1.5	49
56	Interim treatment: Bridging delays to opioid treatment access. <i>Preventive Medicine</i> , 2015, 80, 32-36.	1.6	15
57	Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions: Table 1.. <i>Nicotine and Tobacco Research</i> , 2015, 17, 955-959.	1.4	36
58	Improving medicaid health incentives programs: Lessons from substance abuse treatment research. <i>Preventive Medicine</i> , 2014, 63, 87-89.	1.6	14
59	Spontaneous reductions in smoking during double-blind buprenorphine detoxification. <i>Addictive Behaviors</i> , 2014, 39, 1353-1356.	1.7	10
60	Access to Treatment for Opioid Dependence in Rural America. <i>JAMA Psychiatry</i> , 2014, 71, 359.	6.0	168
61	Contingency Management in Drug Dependence. , 2014, , 1-7.		0
62	Editorial. The prescription opioid abuse epidemic in rural America: A look at how it begins. <i>Journal of Opioid Management</i> , 2014, 10, 225-226.	0.2	1
63	Voucher-based contingency management in the treatment of substance use disorders.. , 2013, , 481-500.		4
64	Characterizing and improving HIV and hepatitis knowledge among primary prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , 2013, 133, 625-632.	1.6	20
65	A Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers. <i>JAMA Psychiatry</i> , 2013, 70, 1347.	6.0	72
66	The use of financial incentives in promoting smoking cessation. <i>Preventive Medicine</i> , 2012, 55, S24-S32.	1.6	113
67	Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 187-199.	1.1	100
68	Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine. <i>Drug and Alcohol Dependence</i> , 2011, 118, 341-348.	1.6	11
69	The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: A review. <i>Drug and Alcohol Dependence</i> , 2011, 119, 1-9.	1.6	53
70	Contingency management for behavior change: Applications to promote brief smoking cessation among opioid-maintained patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2011, 19, 20-30.	1.3	13
71	A contingency-management intervention to promote initial smoking cessation among opioid-maintained patients.. <i>Experimental and Clinical Psychopharmacology</i> , 2010, 18, 37-50.	1.3	61
72	Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. <i>Psychopharmacology</i> , 2009, 204, 573-585.	1.5	70

#	ARTICLE	IF	CITATIONS
73	Brief buprenorphine detoxification for the treatment of prescription opioid dependence: A pilot study. <i>Addictive Behaviors</i> , 2009, 34, 304-311.	1.7	27
74	Effects of Smoking Cessation on Illicit Drug Use among Opioid Maintenance Patients: A Pilot Study. <i>Journal of Drug Issues</i> , 2009, 39, 313-327.	0.6	13
75	Evaluation of ongoing oxycodone abuse among methadone-maintained patients. <i>Journal of Substance Abuse Treatment</i> , 2008, 35, 451-456.	1.5	17
76	VOUCHER-BASED CONTINGENT REINFORCEMENT OF SMOKING ABSTINENCE AMONG METHADONE-MAINTAINED PATIENTS: A PILOT STUDY. <i>Journal of Applied Behavior Analysis</i> , 2008, 41, 527-538.	2.2	58
77	Investigating the pharmacological and nonpharmacological factors that modulate drug reinforcement.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 1-20.	1.3	22
78	Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness. <i>Journal of Substance Abuse Treatment</i> , 2006, 30, 291-295.	1.5	48
79	An injection depot formulation of buprenorphine: extended biodelivery and effects. <i>Addiction</i> , 2006, 101, 420-432.	1.7	52
80	Characterizing the Emerging Population of Prescription Opioid Abusers. <i>American Journal on Addictions</i> , 2006, 15, 208-212.	1.3	84
81	Psychosocial Interventions for Adults with Severe Mental Illnesses and Co-Occurring Substance Use Disorders. <i>Journal of Dual Diagnosis</i> , 2005, 1, 57-82.	0.7	56
82	Use of a low-cost incentive intervention to improve counseling attendance among methadone-maintained patients. <i>Journal of Substance Abuse Treatment</i> , 2005, 29, 253-258.	1.5	32
83	Evaluation of an injection depot formulation of buprenorphine: placebo comparison. <i>Addiction</i> , 2004, 99, 1439-1449.	1.7	40
84	Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. <i>Drug and Alcohol Dependence</i> , 2004, 73, 11-22.	1.6	56
85	Cocaine Abstinence During Methadone Maintenance: Effects of Repeated Brief Exposure to Voucher-Based Reinforcement.. <i>Experimental and Clinical Psychopharmacology</i> , 2004, 12, 269-275.	1.3	11
86	Acute effects of d-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. <i>Psychopharmacology</i> , 2003, 167, 393-402.	1.5	37
87	Community Reinforcement Therapy for Cocaine-Dependent Outpatients. <i>Archives of General Psychiatry</i> , 2003, 60, 1043.	13.8	180
88	Contingent reinforcement of marijuana abstinence among individuals with serious mental illness: A feasibility study.. <i>Experimental and Clinical Psychopharmacology</i> , 2000, 8, 509-517.	1.3	76
89	Implications of behavioral momentum for understanding the behavioral pharmacology of abused drugs. <i>Behavioral and Brain Sciences</i> , 2000, 23, 101-101.	0.4	3